Table 2.
Descriptive analysis of the cohort of sarcoidosis patients
| Sex male, n (%) | 14 (53.8) |
| Age, mean (SD) years | 56.6 (12.6) |
| Weight, mean (SD) Kg | 75.3 (14.7) |
| Height, mean (SD) cm | 169.1 (9.1) |
| Disease Duration, median [IQR] months | 28.4 (7.9, 57,7) |
| Histological diagnosis, n (%) | 26 (100) |
| Age at disease onset, mean (SD) years | 52.8 (4.4) |
| Former smokers, n (%) | 11 (42.3) |
| Scadding radiological stage, n (%) | |
| Stage 0 | 3 (11.5) |
| Stage 1 | 12 (46.2) |
| Stage 2 | 8 (30.8) |
| Stage 3 | 3 (11.5) |
| Stage 4 | 0 (0) |
| Suvmax, mean (SD), abs | 4.4 (4.2) |
| Extrathoracic involvement, n (%) | 15 (57.7) |
| WBC, mean (SD) * 109/L | 7.7 (2.8) |
| Hb, mean (SD) g/dL | 13.2 (1.8) |
| PLT, mean (SD) * 109/L | 260.4 (78.9) |
| CRP, mean (SD), mg/L | 17.3 (25.5) |
| 25-OH D, mean (SD), ng/mL | 22.5 (8.6) |
| Calcium, mean (SD), mg/dL | 9.4 (0.5) |
| ACE, mean (SD) U/L | 44.3 (28.6) |
| Raynaud Phenomenon, n (%) | 3 (11.5) |
| ANA, n (%) | 11 (42.3) |
| ENA, n (%) | 1 (3.8) |
| Therapy, n (%) | |
| Naïve to therapy | |
| Therapy with GCs | 7 (26.9) |
| Ongoing | 8 (30.8) |
| Previous | 19 (73.1) |
| Therapy with cs-/b- DMARDs | 8 (30.8) |
| Pulmonary function tests, mean (SD) % | |
| FVC % | 95.8 (14.7) |
| FEV1% | 87.8 (17.4) |
| DLCO % | 82.2 (14.4) |
| TLC % | 91.4 (12.9) |
ACE angiotensin converting enzyme, ANA anti-nuclear antibodies, DLCO% percent predicted diffusing lung capacity of carbon monoxide (CO), DMARDs Disease Modifying Anti-Rheumatic Drugs, ENA autoantibodies towards extractable nuclear antigens, FEV1% percent predicted forced expiratory volume in 1 s, FVC% percent predicted forced vital capacity, GCs glucocorticoids, IQR interquartile range, n number, SD standard deviation, SUVmax maximum standard uptake volume, TLC% percent predicted total lung capacity, WBC white blood cells, Hb haemoglobin, PLT platelets, CRP C-reactive protein, 25-OH D 25-hydroxyvitamin D, ACE angiotensin converting enzyme